AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02992899 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: O-15 water
Description: Oxygen-15 labelled water is a radioactive variation of regular water, in which the oxygen atom has been replaced by oxygen-15 (15O), a positron-emitting isotope. 15O-water is used as a radioactive tracer for measuring and quantifying blood flow using positron emission tomography (PET) . H2\[15O\] will be prepared on-site in the Emory PET Center cyclotron. During the hours of the test, an intravenous infusion of normal saline will be started to permit the bolus injection of H2\[15O\]. Subjects will receive a 20 mCi intravenous bolus of H2\[15O\] for each of the 14 scans during exposure to neutral and traumatic scripts.
Study NCT03259867 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Trans-arterial tirapazamine embolization
Description: Embolization with Lipiodol and Gelfoam
Study NCT02992899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O-15 water
Description: Oxygen-15 labelled water is a radioactive variation of regular water, in which the oxygen atom has been replaced by oxygen-15 (15O), a positron-emitting isotope. 15O-water is used as a radioactive tracer for measuring and quantifying blood flow using positron emission tomography (PET) . H2\[15O\] will be prepared on-site in the Emory PET Center cyclotron. During the hours of the test, an intravenous infusion of normal saline will be started to permit the bolus injection of H2\[15O\]. Subjects will receive a 20 mCi intravenous bolus of H2\[15O\] for each of the 14 scans during exposure to neutral and traumatic scripts.
Study NCT01590823 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dabigatran Etexilate 110 mg
Description: All participants will receive a single dosage of dabigatran etexilate 110 mg at the start of their 4 hour dialysis session. Blood sampling will be conducted during and up to 48 hours after participant's dialysis session.
Study NCT01284647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teprenone capsule and placebo of sucralfate
Description: Teprenone 1 capsule (50mg)+placebo of sucralfate 4tab, tid×8 weeks.
Study NCT01284647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sucralfate and placebo of teprenone
Description: Placebo of teprenone 1 capsule+ sucralfate 4 tab(1.0), tid×8 weeks
Study NCT01396616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental - Toric Intraocular lenses
Description: Toric Intraocular Lenses will be implenated with cataract patients having astigmatism
Study NCT04745143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMDAE
Description: Use of an NMDA enhancer for the treatment of schizophrenia
Study NCT04745143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cap
Description: Use of placebo as a comparator
Study NCT02002767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velpatasvir
Description: Velpatasvir 100 mg (2 x 50 mg tablets) administered orally
Study NCT02002767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velpatasvir
Description: Velpatasvir 100 mg (2 x 50 mg tablets) administered orally
Study NCT01339533 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Ventilation
Description: Patients who experience problems breathing and require assistance in breathing are placed on a machine that delivers air to the lungs through a tube through the vocal cords. This study is testing 3 protocols for that machine.
Study NCT01339533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation
Description: Patients who experience problems breathing and require assistance in breathing are placed on a machine that delivers air to the lungs through a tube through the vocal cords. This study is testing 3 protocols for that machine.
Study NCT04603430 — intervention group
Intervention type: OTHER
Intervention: Participation in a community wellness program
Description: Participation in the STEPS program, a physical therapy student-run community wellness program for local seniors.
Study NCT00966498 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplant
Description: Peripheral Blood Stem Cell Transplant
Study NCT01503489 — intervention group
Intervention type: DRUG
Intervention: Selective Serotonin Reuptake Inhibitors (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor( SNRI), and Tricyclics.
Description: Risk for antidepressant-associated switch from depression to hypomania, mania, or mixed episode during the 8 weeks after the introduction of an antidepressant or after increasing the dosage of baseline antidepressant.
Study NCT02795286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artis Haemodialysis Machine w/ ASIST Software - Isonatremic
Study NCT02795286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artis Haemodialysis Machine w/ ASIST Software - Isotonic
Study NCT02795286 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Artis Haemodialysis Machine w/o ASIST Software
Study NCT00451620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glyburide
Description: Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.
Study NCT00451620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GlucoNorm
Description: Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.
Study NCT01105247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: 420 mg daily or 840 mg daily
Study NCT03063541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: 100 mg daily as one tablet
Study NCT03063541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intensive blood pressure control
Description: Patients are encouraged to seek any therapy to have a systolic blood pressure of 120 or below. They will be provided with a blood pressure measurement device and are advised to control blood pressure daily.
Study NCT02894203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Study NCT02894203 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Study NCT02104089 — intervention group
Intervention type: DEVICE
Intervention: Zenith® t-Branch™ Thoracoabdominal Endovascular Graft
Description: Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guide the study device(s) into place in the aorta.
Study NCT03756220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy of vitamin C and thiamine
Description: Vitamin C (50 mg/kg up to 3 g, every 12 hours) and thiamine (200 mg every 12 hours) intravenously administered mixed in 50 mL solution bags of normal saline for 2 days
Study NCT03756220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline solution
Description: Normal saline solution in a volume to match the treatment components administered mixed in 50 mL solution bags of normal saline for 2 days
Study NCT03377335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: The subjects in this arm will receive dapagliflozin (10mg daily) as add-on to metformin therapy (doses ranging from 1500 to 3000 mg daily).~Number of patients to be randomized: 93~Number of patients expected to complete the study: >87~All the other medications (including lipid-lowering, anti-hypertensive and anti-platelet agents) will be maintained at fixed doses during the treatment.
Study NCT03377335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: All the subjects in this arm will be on metformin therapy only (doses ranging from 1500 to 3000 mg daily).~Number of patients to be randomized: 93~Number of patients expected to complete the study: >87~All the other medications (including lipid-lowering, anti-hypertensive and anti-platelet agents) will be maintained at fixed doses during the treatment.
Study NCT01991834 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gynecologic laparoscopy
Description: Gynecological laparoscopy without opening hollow viscera.
Study NCT01991834 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: gynecologic laparoscopy
Description: Gynecological laparoscopy without opening hollow viscera.
Study NCT01991834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Intravenous administration of 1 g of cefazolin
Study NCT01991834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration of saline sterile solution
Study NCT00647855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine Sodium Tablets 300 μg
Description: 2x300mcg, single dose fasting
Study NCT00647855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synthroid® Tablets 300 μg
Description: 2x300mcg, single dose fasting
Study NCT02637934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FluorThanatrace
Study NCT02637934 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT imaging sessions
Study NCT03842787 — intervention group
Intervention type: OTHER
Intervention: Biological analysis
Description: Biological and research analysis:~Quantification of ficolin-3, anti-ficolin-3 antibodies, ficolin-2, anti-ficolin-2 antibodies~Purification of patients' antibodies (anti-ficolin-3 and -2)~Evaluation of effects of anti-ficolin-3 and anti-ficolin-2 purified antibodies Investigation of ficolin-3 and ficolin-2 deposition in renal biopsy
Study NCT04162847 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SilverCloud Health Intervention
Description: SilverCloud Health is a mobile mental health platform offering cognitive-behavioral therapy-based guided self-help programs for preventing and treating anxiety, depression, and eating disorders as appropriate Participants in this arm will receive the support of a coach to guide them through the program. Participants will be able to communicate with their coach within the program.
Study NCT01142258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone
Description: Trazodone tablets, 50 mg, 10pm (before bedtime) for 14 days.
Study NCT01142258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive or inert pill which will be used as a comparator
Study NCT01915277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study NCT00103792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: 2000 mg mycophenolate mofetil per day combined with steroids for induction remission, followed by azathioprine standard maintenance therapy
Study NCT00103792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 2 mg/kg/d, combined with steroids, for remission induction, followed by standard azathioprine maintenance therapy
Study NCT01201122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine
Description: Dosing: The current standard of care for pediatric UC is 75mg/kg/day of mesalamine (Pentasa) and should be in multiplications of 500mg (half sachets).~Patients will be randomized in blocks of six stratified by weight groups: 15- \<30 kg, 30-40kg, >40kg.~For body wt. 15- \<20kg Arm: Once daily, 1000 mg (morning) and Placebo (0.5 sachet) (evening). Arm: Twice daily, 500mg (morning) and 500mg (evening).~For body wt: 20- \<30 kg Arm: Once daily, 1500mg (morning) and Placebo (0.5 sachet) (evening). Arm: Twice daily, 1000mg (morning) and 500mg (evening).~For Body wt. 30- \<40 kg Arm: Once daily, 2000mg (morning) and Placebo (1 sachet) (evening). Arm: Twice daily, 1000mg (morning) and 1000mg (evening).~For body wt. ≥40 kg Arm: Once daily, 3000mg (morning) and Placebo (1.5 sachet) (evening). Arm: Twice daily, 1500mg (morning) and 1500mg (evening).
Study NCT04185025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceramides
Description: On the 0th day, it is determined that one of the leg extensions of the participant is the test side using CeraVe Moisturising Lotion and the opposite side is the control side using Half Mu ceramide body milk by the random table. Participants are required to use the product in the morning and evening according to the Product Use Procedures, during which other moisturizing products or emollients are prohibited. And the follow-up tests are conducted at the prescribed time. At each visit, empty packaging of products used during this period must be collected; if they are not used up as required, the remaining products must be collected.
Study NCT04185025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceramides
Description: On the 0th day, it is determined that one of the leg extensions of the participant is the test side using CeraVe Moisturising Lotion and the opposite side is the control side using Half Mu ceramide body milk by the random table. Participants are required to use the product in the morning and evening according to the Product Use Procedures, during which other moisturizing products or emollients are prohibited. And the follow-up tests are conducted at the prescribed time. At each visit, empty packaging of products used during this period must be collected; if they are not used up as required, the remaining products must be collected.
Study NCT04145791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice
Description: ice packs
Study NCT03477890 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Stratified medicine involving a diagnostic intervention
Description: Adjunctive tests of coronary artery lesion severity (fractional flow reserve) and function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with obstructive coronary artery disease (mis-classified by non-invasive CTCA) or no-obstructive coronary disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results).~Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013), Scottish Intercollegiate Guideline Network (SIGN), 2017).
Study NCT03477890 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Stratified medicine involving a diagnostic intervention
Description: Adjunctive tests of coronary artery lesion severity (fractional flow reserve) and function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with obstructive coronary artery disease (mis-classified by non-invasive CTCA) or non-obstructive coronary disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results).~Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013), Scottish Intercollegiate Guideline Network (SIGN), 2017).
Study NCT03296696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 596
Description: Drug
Study NCT03296696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 404
Description: Drug
Study NCT02700230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT02700230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02700230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Description: Given intratumorally
Study NCT02700230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02700230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT imaging
Study NCT02700230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT02700230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo ultrasound imaging
Study NCT02700230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02700230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy
Study NCT02700230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02409615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypnosis Therapy
Description: A technique called Wakeful Hypnosis that involves suggestions for healing given to a person while in a normal state of consciousness
Study NCT02409615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healing Touch Therapy
Description: Healing Touch An energery based therapy that uses light body or above body touch to help balance the energy field and energy centers of the body to restore harmony within the body for greater healing.
Study NCT00825669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: TACE: The chemotherapeutic drugs and 2 to 10 ml lipiodol are given via hepatica propria artery. The chemotherapeutic drugs include 5-Fu 1500 mg, epirubicin 30 mg, cisplatin 30 mg.
Study NCT00825669 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser ablation
Description: Laser ablation is given to the PVTT.
Study NCT02989467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: Subjects will receive one tablet daily for 5 consecutive days. On Day 1 subjects will take a 125mg tablet, on Days 2-5, subjects will take an 80 mg tablet.
Study NCT02989467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive one placebo tablet daily for 5 consecutive days.
Study NCT01190202 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Capillary blood samples collected by finger/heel prick
Study NCT01190202 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assessment of body temperature
Description: Assessment of axial body temperature with a digital thermometer
Study NCT00871806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Commercial tablet with water
Description: 40 mg tablet, given once to each subject
Study NCT00871806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODT #1 without water
Description: 40 mg tablet given once to each subject
Study NCT00871806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODT #2 without water
Description: 40 mg tablet given once to each subject
Study NCT00871806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODT #1 with water
Description: 40 mg tablet given once to each subject
Study NCT00871806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODT #2 with water
Description: 40 mg tablet given once to each subject
Study NCT00171899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study NCT01321970 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stress ultrasound
Description: Qualitative interpretation of the left ventricular wall motion abnormalities is performed in real time in the resting phase and during pharmacological stress. The translation of quantitative data is then performed for each of the 17 segments on a bulls-eye pattern identical to that of scintigraphy.
Study NCT01321970 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Scintigraphy
Description: Image acquisition is synchronized to the electrocardiogram. The tomographic sections are represented in the 3 directions of space, the analysis is also done on the classical representation in 17 segments. (Typically used in ultrasound perfusion scintigraphy or PET).
Study NCT01321970 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronary angiography
Description: Performed in interventional cardiology setting using a guide introduced through the radial or femoral artery. The injection of iodine allows opacification of coronary arteries and their visualization by fluoroscopy. The qualitative interpretation of the data is translated in terms of percentage of stenosis of the coronary artery. It is thus considered that the stenosis is significant at over 70% obstruction of the lumenal diameter. This interpretation is made for each of the three main coronary arteries and their tributaries:~* Right coronary (proximal, middle and distal) and collateral (inter ventricular posterior ventricular posterior retro)~* Inter ventricular anterior (proximal, middle and distal) and its tributaries (diagonal and septal)~* Circumflex (proximal, middle and distal) and collateral (first and second marginal)
Study NCT05246150 — intervention group
Intervention type: BEHAVIORAL
Intervention: nursing care practices
Description: To determine the effect of nursing care practices on Near Infrared Spectroscopy (NIRS) levels in premature babies
Study NCT03151707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside
Description: Nicotinamide riboside 2g/day for a 2 week duration